MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2026.07.055

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2026

Clinical Outcomes of Minibeam Radiotherapy for Superficial Skin and Soft Tissue Malignancies.

Chauhan Kiran K, Grams Michael P, Lee Minji K, Park Sean S, Rajkumar Anne W, Garcia Darwin A, Morris Jonathan M, Mateus Chrystian Quintero, Dudek Arkadiusz Z, Guenzel Rachael M, Kottschade Lisa A, Laack Nadia N, Corbin Kimberly S, Stish Bradley J, Lester Scott C, Mutter Robert W

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Minibeam radiotherapy (MBRT) is a spatially fractionated technique delivering alternating submillimeter high-dose peak and low-dose valley regions using orthovoltage x rays. Preclinical studies have demonstrated normal tissue sparing and antitumor activity, but clinical data are limited. Following a prior report of commissioning and treatment in 2 patients, we report the first clinical series evaluating clinical outcomes with MBRT for superficial malignancies.

METHODS AND MATERIALS: Patients with superficial cutaneous and soft tissue malignancies were treated with MBRT at a single institution using a clinical orthovoltage unit and tungsten collimators producing 0.5-mm beams spaced 1.1 mm center to center. Cumulative incidence functions were used to estimate local progression. Toxicity was graded by Common Terminology Criteria for Adverse Events v5.0.

RESULTS

Thirty-six patients with 46 lesions were treated between December 2023 and August 2025; 85% received MBRT alone. Median follow-up was 15.1 months. Median peak and valley doses per fraction were 25.9 Gy and 3.4 Gy, respectively; median number of fractions was 2. Patients were heavily pretreated, with 90% receiving ≥2 prior systemic therapies and 43% prior radiation. Symptomatic improvement occurred in 86%. Among 40 evaluable lesions, complete response occurred in 22.5%, partial response in 25%, and stable disease in 45%. Twelve-month local progression was 11% overall and 8% for MBRT alone. Documented abscopal responses occurred in 11% without systemic therapy changes. Grade 1-2 dermatitis occurred in 61%; 2 grade 3 adverse events occurred in patients with baseline tissue compromise. No grade 4-5 toxicities were observed.

CONCLUSIONS

MBRT was well tolerated and yielded encouraging symptomatic benefits and local control in treatment-refractory superficial malignancies.

Для цитирования: Chauhan Kiran K, Grams Michael P, Lee Minji K, Park Sean S, Rajkumar Anne W, Garcia Darwin A, Morris Jonathan M, Mateus Chrystian Quintero, Dudek Arkadiusz Z, Guenzel Rachael M, Kottschade Lisa A, Laack Nadia N, Corbin Kimberly S, Stish Bradley J, Lester Scott C, Mutter Robert W. Clinical Outcomes of Minibeam Radiotherapy for Superficial Skin and Soft Tissue Malignancies.. International journal of radiation oncology, biology, physics. 2026. DOI: 10.1016/j.ijrobp.2026.07.055.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.